Keros director buys 1,000 shares at $10.27

Keros Therapeutics, Inc. (KROS) director Jean Jacques Bienaime reported an open-market purchase of common stock.

Rhea-AI Filing Summary

Keros Therapeutics, Inc. (KROS) director Jean Jacques Bienaime reported an open-market purchase of common stock. On 2026-08-17, he purchased 1,000 shares at a weighted average price of $10.27 per share, executed in multiple trades between $10.02 and $10.39. Following this transaction, he directly holds 19,592 shares of Keros Therapeutics common stock. The purchase was made pursuant to a Rule 10b5-1 trading plan adopted on December 5, 2025.

Insider Trade Summary 10b5-1

Net Buyer: 1,000 shares

Net Buy 1 txn

Insider BIENAIME JEAN JACQUES

Role Director

Bought 1,000 shs ($10K)

Type	Security	Shares	Price	Value
Purchase	Common Stock F1, F2	1,000	$10.27	$10K

Holdings After Transaction: Common Stock — 19,592 shares (Direct)

Footnotes (2)

1. F1. Shares were purchased pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.
2. F2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.02 to $10.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Key Figures

Shares purchased: 1,000 shares Weighted average purchase price: $10.27 per share Price range of purchases: $10.02 to $10.39 per share +3 more

6 metrics

Shares purchased 1,000 shares Common stock purchased on 2026-08-17 in open-market transactions

Weighted average purchase price $10.27 per share Average price for the 1,000 KROS shares bought on 2026-08-17

Price range of purchases $10.02 to $10.39 per share Range of prices for multiple transactions comprising the 1,000-share purchase

Shares owned after transaction 19,592 shares Directly owned Keros Therapeutics common shares following the reported purchase

Net buy shares in filing 1,000 shares Transaction summary net buy-sell shares for this Form 4

10b5-1 plan adoption date December 5, 2025 Adoption date of the Rule 10b5-1 trading plan governing the reported trades

Key Terms

Rule 10b5-1 trading plan, weighted average price, multiple transactions

3 terms

Rule 10b5-1 trading plan regulatory

"Shares were purchased pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

multiple transactions financial

"These shares were purchased in multiple transactions at prices ranging"

FAQ

What insider transaction did KROS director Jean Jacques Bienaime report on this Form 4?

Jean Jacques Bienaime reported buying 1,000 shares of Keros Therapeutics (KROS) common stock on 2026-08-17. The shares were purchased in open-market transactions under a Rule 10b5-1 trading plan at a weighted average price of $10.27 per share.

At what price did the KROS insider purchase shares on 2026-08-17?

The insider’s reported weighted average purchase price was $10.27 per share. According to the filing, the 1,000 shares were acquired in multiple transactions at prices ranging from $10.02 to $10.39 inclusive in the open market.

How many KROS shares does Jean Jacques Bienaime own after this reported transaction?

After the reported transaction, Jean Jacques Bienaime directly owns 19,592 shares of Keros Therapeutics (KROS) common stock. This figure reflects his holdings following the 1,000-share open-market purchase disclosed for the 2026-08-17 trade date.

Was the recent KROS insider share purchase made under a Rule 10b5-1 trading plan?

Yes. The filing states the 1,000-share purchase was made pursuant to a Rule 10b5-1 trading plan. The plan was adopted by the reporting person on December 5, 2025, indicating the trades were pre-arranged rather than opportunistic.

How many KROS shares in total did the insider buy or sell in this Form 4?

The Form 4 reports that the insider had net purchases of 1,000 shares of Keros Therapeutics (KROS). The transaction summary shows 1 buy transaction totaling 1,000 shares and no reported sales or derivative exercises in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/19/2026 - 04:10 PM Accepted by SEC EDGAR 08/19/2026 - 04:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BIENAIME JEAN JACQUES

(Last) (First) (Middle)

C/O KEROS THERAPEUTICS, INC.

1050 WALTHAM STREET, SUITE 302

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Keros Therapeutics, Inc. [ KROS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/17/2026		P(1)		1,000	A	$10.27(2)	19,592	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares were purchased pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.02 to $10.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

	/s/ Esther Cho, Attorney-in-Fact	08/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)